JNJ — Johnson & Johnson

As of 2026-10-14 the near-term tape was clearly negative — JNJ was down 3.62% over one week and 6.47% over one month, RSI(14) at 35.1, price 5.19% below the SMA20 and 6.09% below the SMA50 — driven by the Oct-13 Q3 2026 release where a $5.5B talc reserve cratered GAAP EPS to $0.086 and MedTech revenue slightly missed. That negative price/headline reaction is offset by genuinely constructive fundamentals: revenue and adjusted EPS both beat, the pharma arm grew on Tremfya/Darzalex strength, the sell-side consensus remains Buy with price targets around $283-285 (well above the $251.06 print), and the stock still holds above its 200-day SMA. Net: sentiment is cautious and event-driven rather than outright bearish, hence Neutral.

Revenue growth is solid but decelerating at the margin: Q3 2026 revenue of $25.40B was up 5.9% YoY versus +6.6% in Q2 2026, +9.9% in Q1 2026 and +9.1% in Q4 2025 — still mid-to-high single digits, but off the ~9-10% pace of late 2025/early 2026. Operating income has been stable at roughly $6.4-7.2B per quarter with a ~24-28% operating margin, though Q3 2026 margin compressed to ~25.1% ($6.365B) from ~29.6% a year earlier as R&D expense jumped to $4.652B from $3.672B. The GAAP net income line is heavily distorted by one-offs — the $11.0B/$4.54 EPS quarter in Q1 2025 (one-time gain) and the $0.210B/$0.086 EPS in Q3 2026 (the talc reserve) are not representative of underlying earnings power, which has been running ~$2.1-2.3 per quarter. Free cash flow is lumpy ($1.5B-$8.4B per quarter) but the trailing four reported quarters totaled ~$18.7B versus ~$16.4B for the prior four — roughly +14%. Net read: a stable, moderately growing business with an event-driven GAAP distortion, not a structural inflection in either direction.

As of 2026-10-14, the trailing P/E of 38.06x is meaningless in isolation because TTM EPS of $6.576 includes the $0.086 talc-hit quarter; the forward lens is what matters. At the $251.06 price, JNJ trades at roughly 22.4x 2027 consensus EPS of $11.21 and ~22.6x the 2026 guidance midpoint of ~$11.10 — a clear premium to its 5-year average trailing P/E of 20.43x and to its 5-year average P/S of 5.08x versus the current 6.09x. The PEG ratio (-1.037) is negative and useless here. Verdict: fair-to-modestly-expensive — you are paying a premium multiple for a low-beta (0.235) defensive compounder growing revenue ~6%, which the deterministic score's overlay correctly labels 'Rich vs. its own history.'

At ~22x forward earnings against ~6% topline and high-single-digit adjusted EPS growth, the price already embeds steady, low-drama compounding — not a re-acceleration. The upside skew therefore has to come from multiple expansion (clearing the talc overhang) or faster pipeline contribution (oncology, Tremfya, Rybrevant, TAR-210), while the downside is a growth slip (Stelara biosimilar erosion outrunning new launches) or a larger-than-feared settlement, either of which would make 22x hard to defend and push the stock toward 19-20x (roughly $213-224 on ~$11.2 EPS). In short: earnings are being priced as reliable, so the risk/reward is roughly balanced rather than skewed up.

As of 2026-10-14, RSI(14) was 35.1 — weak and approaching oversold but not yet at the <30 extreme — with the $251.06 price sitting 5.19% below the SMA20 and 6.09% below the SMA50 (a short-term downtrend) while still 2.25% above the SMA200 (the medium-term uptrend is intact). Returns of -3.62% (1wk), -6.47% (1mo), +0.84% (3mo) and +4.37% (6mo) confirm this is a pullback within an uptrend, not a breakdown. Entry-timing implication: momentum has turned negative and a bottom is not confirmed — waiting for RSI to stabilize above ~40-45 or for a reclaim of the 50-day SMA is more prudent than catching a falling knife, though the stock is nearer value now than it was a month ago.

• Talc litigation and legal overhang: the $5.5B reserve is the single largest swing factor on sentiment and cash flow, with ongoing court milestones and plaintiff-approval risk.
• Drug-pricing reform and potential pharma tariffs: U.S. policy pressure on branded drug pricing and import tariffs could compress Innovative Medicine margins.
• Biosimilar erosion: legacy blockbusters such as Stelara continue losing revenue to biosimilars, putting execution pressure on newer launches.
• Interest rates and defensive rotation: with a 0.235 beta and a 1.93% dividend (64-year growth streak), JNJ is a classic risk-off beneficiary whose relative multiple moves with rate expectations.
• MedTech demand and global healthcare spend: surgical/orthopedic procedure volumes and hospital capex drive the MedTech arm (which missed in Q3 2026), while roughly half of revenue is ex-U.S. and exposed to FX and foreign pricing pressure.

• Talc settlement execution: plaintiff approval and movement on the $5.5B framework would remove a multi-year overhang and could drive multiple expansion.
• Pipeline commercial ramp and readouts: Tremfya expansions, Rybrevant, TAR-210 and other oncology assets targeting a multi-billion-dollar footprint by 2030.
• Q4 2026 results (estimated 2027-01-26): the first clean read post-reserve, plus initial 2027 guidance.
• Annual dividend increase (typically announced early in the year), extending the 64-year streak.
• MedTech recovery: any rebound in procedure volumes and device demand after the Q3 2026 revenue miss.

• The $5.5B talc reserve proves insufficient and legal costs escalate further.
• Stelara and other biosimilar erosion outpaces the new-product ramp, slowing Innovative Medicine growth.
• Rich valuation: ~22x forward versus a 20.4x 5-year average leaves little cushion for a growth or margin miss.
• Operating margin compression (Q3 2026 ~25.1% vs ~29.6% a year earlier) if the R&D step-up and one-off charges persist.
• U.S. drug-pricing reform and pharma tariffs compressing margins across the Innovative Medicine portfolio.

JNJ is a high-quality, low-beta defensive compounder with an intact pharma growth engine (revenue ~+6% YoY, TTM free cash flow up ~14%) and a fortress balance sheet ($20.4B cash vs $37.3B long-term debt), but as of 2026-10-14 it is fairly-to-slightly-fully valued at ~22x forward earnings for ~6% growth, with a real talc overhang and a negative short-term tape. This is not a screaming buy; it is a reasonable hold/accumulate-on-further-weakness name, where the $5.5B reserve is both a genuine cash cost and a step toward resolving a multi-year legal drag that, if cleared, could re-rate the multiple.

Applied a 22x forward P/E — a modest premium to JNJ's 5-year average trailing P/E of 20.43x, justified by its 0.235 beta, 64-year dividend-growth record and strong balance sheet but capped by the talc overhang and Stelara biosimilar erosion — to a forward EPS of ~$11.2 (blending the 2026 guidance midpoint of ~$11.10 and 2027 consensus of $11.21), giving ~$246-247; cross-checked against a normalized ~$19.5B free cash flow at a ~3.3-3.5% yield (~$240-255) and a dividend-discount model at an 8% required return / 6% growth (~$257).